London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

In other developments, the ECDC today reported a slow rise in COVID activity in the Europe, which may partly reflect waning ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

U.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

领先制药公司GSK plc (LSE/NYSE:GSK)今日宣布，欧洲药品管理局 (EMA)已开始审查其佐剂重组呼吸道合胞病毒 (RSV)疫苗Arexvy用于18岁及以上成人的申请。该疫苗目前已获准用于老年人群，预计将在2026年上半年获得监管决定。

LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory ...

Investing.com - 周五开盘时，英国股市下滑，英镑兑美元下跌，这主要受到中东局势升级的拖累，以色列对伊朗的袭击引发了全球市场的普遍下跌。 葛兰素史克 (GSK plc) (LON: GSK )周五表示，欧洲药品管理局 (EMA)已接受其请求，扩大其呼吸道合胞病毒 (RSV)疫苗Arexvy的批准年龄范围，将包括18岁及以上人群。